Digital Biomarkers Market Size, Share & Trends Analysis Report By Applications (Sleep and Movement Disorders, Cardiovascular, Psychiatric Disorders (Mood and Behavior), Chronic Pain, Neurodegenerative Diseases, Diabetes, Respiratory Diseases, Others), By System Components, By Type, by End-User, Region And Segment Forecasts, 2023-2031

Report Id: 1937 Pages: 180 Last Updated: 18 October 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

The Digital Biomarkers Market Size is valued at 2.66 Billion in 2022 and is predicted to reach 17.58 Billion by the year 2031 at a 23.52 % CAGR during the forecast period for 2023-2031.

Digital Biomarkers Market

Digital Biomarkers are nothing, but the data measured through specific devices to help researchers and doctors track healthy processes, diagnose diseases and other health conditions, monitor responses to medication, and identify health risks in a person. The digital biomarker could potentially facilitate the effective use of a DHT in evaluating a therapeutic product, potentially growing patient access to safe and effective medical products. It can detect non-biological external factors (e.g., environmental features like pollen count) and provides an opportunity to identify predictors and influences on health, which will require the systematic development of scientific evidence in the future.

Passive digital biomarkers are simple digital biomarkers that are collected via unnoticed actions. Passive data from sensors integrated into wearable devices is generated when a user wears the device. Active digital biomarkers are digital biomarkers collected via prompted actions. Digital biomarker data can be generated and captured from smart devices, such as smartphones and tablets, when a user interacts with the device in response to an active prompt.

Biomarkers are popular nowadays in drug development, so it is widely used, positively affecting the market growth. Factors such as the rising employment of vocal digital biomarkers and regulatory flexibility toward digital healthcare are also responsible for the growth of the digital biomarkers market. Vast use of wearable smart devices and smartphone applications in healthcare will continually fuel the market. Failure of Drugs for Neurodegenerative Disorders accelerates the requirement of digital biomarkers.

The increasing innovations and product designs in the global market and the growing use in emerging economies are the driving factors for the market's growth. The increasing number of product launches and rising number of Food and Drug Administration (FDA) approvals are forecast to propel the market growth. In 2019, FDA granted  an approval to KardiaMobile ( AliveCor). It is an AI-enabled wearable device that monitors the vital signs connected to heart arrhythmias. Earlier, Altoida Raises $6.3M Series A to Predict Alzheimer's Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality.

Need for Standardized and Interoperable Solutions, Incorrectness in Data Measurements, Lack of Integration, Interoperability between Medical Records & User Generated Data, Lack of Use Cases of the Return on Investment (ROI) Analysis and high costing, these are the prominent factors which will restrain the progress of digital biomarkers market. 

Competitive Landscape:

Some of The Key Players in The Digital Biomarkers Market: 

  • Alphabet Inc.
  • AliveCor Inc.
  • Akili Interactive Labs, Inc.
  • Cambridge Cognition Ltd
  • Dassault Systèmes
  • IXICO plc
  • Koninklijke Philips N.V
  • Shimmer
  • Quanterix Corporation
  • Altoida AG
  • Evidation Health, Inc.
  • Happify, Inc.
  • Huma
  • Human API
  • Mindstrong Health
  • Neurotrack Technologies, Inc
  • Orikami
  • Winterlight Labs Inc. 

Key Developments in the Market:

  • In Mar 2022, Altoida's additional capital brings the series A financing round to $20.3 million. The precision neurology company will use the funds to advance its first in class ai-powered neurocognitive assessment platform.
  • In Jan 2021, Happify launched a digital wellness program called "Claro" with Happify, which develops digital therapeutics for people with chronic diseases, leaning on its team of scientists, physicians and gaming experts to help people manage mental health. 

Market Segmentation:

The market is segmented into Application, System Components, Type, End-User and Region. Based on Application, the market is segmented into Sleep and Movement Disorders, Cardiovascular, Psychiatric Disorders (Mood and Behavior), Chronic Pain, Neurodegenerative Diseases, Diabetes, Respiratory Diseases, and Others. On the other hand system components segment is divided into Data Collection Tools (Wearables Devices, Implantable and Mobile Applications) and Data Integration Software. The Type segment consists of Clinical Trials and Clinical Settings. The last segment is the End-User segment which is divided into Biopharmaceutical Companies, Payers and Providers.

North America is forecast to hold the main share in the global digital biomarkers market. The presence of leading industry players is expected to contribute to regional development in the global digital biomarkers market. 

The Digital Biomarkers Market Report Scope:

Report Attribute Specifications
Market Size Value In 2022 USD 2.66 Billion
Revenue Forecast In 2031 USD 17.58 Billion
Growth Rate CAGR CAGR of 23.52 % from 2023 to 2031
Quantitative Units Representation of revenue in US$ Million and CAGR from 2023 to 2031
Historic Year 2019 to 2022
Forecast Year 2023-2031
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered By Applications, By System Components, By Type, by End-User
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia
Competitive Landscape Alphabet Inc., AliveCor Inc., Akili Interactive Labs, Inc., Cambridge Cognition Ltd, Dassault Systèmes, IXICO plc, Koninklijke Philips N.V, Shimmer ,  Quanterix Corporation, Altoida AG, Evidation Health, Inc., Happify, Inc., Huma, Human API, Mindstrong Health, Neurotrack Technologies, Inc, Orikami, Winterlight Labs Inc.
Customization Scope Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing and Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Segmentation of Digital Biomarkers Market:

Global Digital Biomarkers Market, by Application, 2023-2031 (Value US$ Mn)

  • Sleep and Movement Disorders
  • Cardiovascular
  • Psychiatric Disorders (Mood and Behavior)
  • Chronic Pain
  • Neurodegenerative Diseases
  • Diabetes
  • Respiratory Diseases
  • Others

Digital Biomarkers Market

Global Digital Biomarkers Market, by System Components, 2023-2031 (Value US$ Mn)

  • Data Collection Tools
    • Wearables Devices
    • Implantables
    • Mobile Applications
  • Data Integration Software

Global Digital Biomarkers Market, by Type, 2023-2031 (Value US$ Mn)

  • Clinical trials
  • Clinical settings

Global Digital Biomarkers Market, by End-User, 2023-2031 (Value US$ Mn)

  • Biopharmaceutical Companies
  • Payers
  • Providers

Global Digital Biomarkers Market, by Region, 2023-2031 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Digital Biomarkers Market, by Country, 2023-2031 (Value US$ Mn)

  • U.S.
  • Canada

Europe Digital Biomarkers Market, by Country, 2023-2031 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Digital Biomarkers Market, by Country, 2023-2031 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Digital Biomarkers Market, by Country, 2023-2031 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Digital Biomarkers Market, by Country, 2023-2031 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
7821
Security Code field cannot be blank!

Frequently Asked Questions

Digital Biomarkers Market Size is valued at 2.66 Billion in 2022 and is predicted to reach 17.58 Billion by the year 2031

Digital Biomarkers Market expected to grow at a 23.52 % CAGR during the forecast period for 2023-2031

Alphabet Inc., AliveCor Inc., Akili Interactive Labs, Inc., Cambridge Cognition Ltd, Dassault Systèmes, IXICO plc, Koninklijke Philips N.V, Shimmer ,
Get Sample Report Enquiry Before Buying